What To Know
- He brings to Windtree a deep understanding of our industry and corporate financial management, and his overall business acumen, insights and expertise will support Windtree’s efforts to build on its current momentum and create value in the future.
- “Windtree’s recent merger with CVie Therapeutics has given the Company a global presence and a larger therapeutic footprint than in the past.
Daniel Geffken has been appointed to Windtreee Therapeutics board of directors effective April 24, 2019. The news was announced today.
Windtree Therapeutics, Inc. (OTCQB: WINT), a biopharmaceutical and medical device company focused on developing novel therapies to address significant unmet needs in important acute care markets.
“As we continue to support Windtree in the delivery of near-term and sustainable growth, it is with great pleasure that we welcome Daniel to our Board,” said James Huang, Windtree’s Chairman of the Board. “Daniel’s track record of success spans many decades. He brings to Windtree a deep understanding of our industry and corporate financial management, and his overall business acumen, insights and expertise will support Windtree’s efforts to build on its current momentum and create value in the future.”
Since 2011, Mr. Geffken has been serving as the Founding Managing Partner of Danforth Advisors, a leading financial and strategy consulting firm to the life sciences industry. He has served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, Cabaletta Bio, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Mr. Geffken has served on the Board of Directors of Elicio Bio, Alcobra Ltd. and Arcturus Inc., after its merger with Alcobra. Since 2013, he has assisted in ten initial public offering filings. Over the course of his career, he has assisted in raising more than $1 billion in equity and debt securities for life science companies.
“I am pleased to join a great team of directors on Windtree’s board, especially during this transformational time for the Company,” said Mr. Geffken. “Windtree’s recent merger with CVie Therapeutics has given the Company a global presence and a larger therapeutic footprint than in the past. This translates into more avenues for growth and value generation and, for me, an exciting opportunity to contribute to their success.”
Mr. Geffken will serve as Chairman of the Board’s Audit Committee and as a member of the Compensation Committee.
